Correction: Corrêa Rassele et al. Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF) in Primary Canine Mast Cell Tumors and Related Regional Lymph Node Metastasis. Animals 2025, 15, 283

Newly Added Table

In the original publication [1], Table 5, which refers to the Results was missing;

Table 5. Pearson correlation with respective p and r values in 28 dogs with cutaneous mast cell tumors.

	p < 0.05	R Correlation
Kiupel grade
Tumor Necrosis	0.004	0.520
Tumor Ulceration	0.004	0.520
Patnaik’s Graduation	0.001	0.560
Mitotic Index	0.0001	0.665
Lymph Node Classification	0.001	0.567
Paraneoplastic Syndromes	0.006	−0.500
Patnaik grade
Tumor Necrosis	0.0002	0.633
Ulceration	0.019	0.440
Paraneoplastic Syndromes	0.019	−0.438
Mitotic Index
Tumor Necrosis	0.010	0.478
Tumor Ulceration	0.006	0.503
Lymph Node Classification	0.003	0.530
Lymph Node Classification
Tumor Necrosis	0.007	0.493
Tumor Ulceration	0.007	0.493
Tumor Ulceration
Paraneoplastic Syndromes	0.003	−0.530
Tumor Location
Tumor Size	0.010	−0.475
VEGF in the tumor
Tumor Size	0.016	0.258
Paraneoplastic Syndromes
Recurrence	0.018	0.441
Death related to mast cell tumor
Kiupel grade	0.004	−0.520
Tumor Size	0.038	−0.392
Recurrence	0.002	0.547
Survival
Kiupel grade	0.031	−0.406
Mitotic index	0.047	0.378
Tumor necrosis	0.025	−0.422
Tumor location	0.005	−0.509
Systemic Treatment	0.017	−0.445
Chemotherapy
Breed	0.0003	0.623
Size	0.012	−0.225

is shown below.

Update Corresponding Author and Author Contribution

Andrigo Barboza de Nardi was included as a corresponding author as he also participated on Conceptualization, Methodology, Formal Analysis, Writing—Original Draft Preparation, Writing—Review and Editing, Supervision. The study was also performed in collaboration with Universidade Estadual Paulista (UNESP). Andrigo Barboza de Nardi’s telephone number is Tel.: +55-16-3209-7247.

Text Correction

There was an error in the original publication. On Discussion, paragraph 12, it is stated that “In the present study, only 21.4% of patients expressed VEGF in both primary tumor and metastasis, with fair agreement.” The percentage presented must be replaced by 14.8% as in the results previously presented: “In the present study, only 14.8% of patients expressed VEGF in both primary tumor and metastasis, with fair agreement.”

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.